Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAVEMACS-D avelumab maintenance database study in Japanese urothelial carcinoma
jRCT1031240122Completed
- Sponsor
- Merck KGaA
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Single-arm trial of avelumab in transitional cell carcinoma (TCC), sponsored by Merck KGaA. Primary endpoints: Baseline demographics and clinical characteristics, Characteristics of first platinum-based combination chemotherapy and 1 more. Started May 2024; status: completed.
02
Drugs
avelumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT1031240122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031240122.